I-Mab ADR (NASDAQ: IMAB) on Monday, soared 14.91% from the previous trading day, before settling in for the closing price of $0.94. Within the past 52 weeks, IMAB’s price has moved between $0.84 and $2.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1181.20% over the past five years. The company achieved an average annual earnings per share of 87.13%. With a float of $76.81 million, this company’s outstanding shares have now reached $77.02 million.
Let’s look at the performance matrix of the company that is accounted for 220 employees. In terms of profitability, gross margin is 100.0%, operating margin of -10017.88%, and the pretax margin is -12176.93%.
I-Mab ADR (IMAB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of I-Mab ADR is 0.27%, while institutional ownership is 18.64%. The most recent insider transaction that took place on Jul 26 ’24, was worth 69,500.
I-Mab ADR (IMAB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.00% during the next five years compared to -18.89% drop over the previous five years of trading.
I-Mab ADR (NASDAQ: IMAB) Trading Performance Indicators
I-Mab ADR (IMAB) is currently performing well based on its current performance indicators. A quick ratio of 16.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 75.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of I-Mab ADR (IMAB)
I-Mab ADR (NASDAQ: IMAB) saw its 5-day average volume 0.87 million, a negative change from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 48.68%. Additionally, its Average True Range was 0.10.
During the past 100 days, I-Mab ADR’s (IMAB) raw stochastic average was set at 29.91%, which indicates a significant decrease from 42.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.63% in the past 14 days, which was higher than the 78.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0155, while its 200-day Moving Average is $1.3895. Nevertheless, the first resistance level for the watch stands at $1.3233 in the near term. At $1.5667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7333. If the price goes on to break the first support level at $0.9133, it is likely to go to the next support level at $0.7467. The third support level lies at $0.5033 if the price breaches the second support level.
I-Mab ADR (NASDAQ: IMAB) Key Stats
Market capitalization of the company is 83.18 million based on 81,501K outstanding shares. Right now, sales total 3,890 K and income totals -206,440 K. The company made 0 K in profit during its latest quarter, and 25,130 K in sales during its previous quarter.
